Eden Research (EDEN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 4.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 11.85
  • 52 Week Low: 3.40
  • Currency: UK Pounds
  • Shares Issued: 533.35m
  • Volume: 255,065
  • Market Cap: £22.67m

Eden Research narrows losses on massive revenue gains

By Iain Gilbert

Date: Tuesday 20 Mar 2018

LONDON (ShareCast) - (ShareCast News) - AIM-quoted biopesticide and natural microencapsulation technology firm Eden Research narrowed losses last year thanks to a significant boost in revenue.
Eden's revenue grew like the proverbial beanstalk, up 375% to £1.9m in 2017, leading to a 57.89% year-on-year decrease in pre-tax losses to £800,000. Net cash balances were boosted to £3.7m from £1.5m.

Throughout the year Eden signed multiple commercial agreements with Sipcam, including an evaluation and option agreement, for which the Italian agrochemical giant paid a fee of €600,000 to Eden, establishing a long-term collaborative partnership between the two.

Eden also received EU approval for its first agrochemical, fungicide product, Mevalone, with first sales being achieved in France shortly thereafter as the firm waited on various approvals and patent protection in Cyprus, Albania, Portugal, Spain, Greece and the United States.

Tom Lupton retired as Eden's chairman and non-executive director on 31 December 2017.

Lykele van der Broek, Lupton's replacement as chairman, said, "Significant progress was made in 2017 and it is particularly pleasing that our first fungicide product, Mevalone, is now in the top three wine producing countries in the world. This is a major milestone for the company and sets a good platform from which we can build.

"The strong growth achieved in 2017, driven by new regulatory approvals, is expected to continue in the current year and consequently the board remains confident that 2018 will be another year of strategic and financial progress," van der Broek concluded.

As of 1120 GMT, shares had grown 4.53% to 8.36p.

House broker Shore Capital said: "Management now seems to be building a more sustainable commercial platform with 41% of revenues generated from product sales compared to licence agreement royalties in FY2017. We expect this to grow in the coming year and beyond as management look to continue to develop its product portfolio amid a market that is increasingly adopting biological products."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Eden Research Market Data

Currency UK Pounds
Share Price 4.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 11.85
52 Week Low 3.40
Volume 255,065
Shares Issued 533.35m
Market Cap £22.67m

Eden Research Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
33.98% below the market average33.98% below the market average33.98% below the market average33.98% below the market average33.98% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income Not Available
Growth
5.67% above the market average5.67% above the market average5.67% above the market average5.67% above the market average5.67% above the market average
5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average

Eden Research Dividends

No dividends found

Trades for 26-Apr-2024

Time Volume / Share Price
15:25 10,000 @ 4.33p
13:14 8,000 @ 4.33p
12:31 15,000 @ 4.34p
12:18 7,533 @ 4.34p
12:18 7,936 @ 4.17p

Eden Research Key Personnel

CFO Alexander John Abrey
CEO Sean M. Smith

Top of Page